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AbstrAct
Introduction Asthma is associated with many comorbid 
conditions that have the potential to impact on its 
management, control and outcomes. These comorbid 
conditions have the potential to impact on healthcare 
expenditure. We plan to undertake a systematic review 
to synthesise the evidence on the healthcare costs 
associated with asthma comorbidity.
Methods and analysis We will systematically search 
the following electronic databases between January 
2000 and January 2017: National Health Service (NHS) 
Economic Evaluation Database, Google Scholar, Allied 
and Complementary Medicine Database (AMED), Global 
Health, PsychINFO, Medline, Embase, Institute for Scientific 
Information Web of Science and Cumulative Index to 
Nursing and Allied Health Literature. We will search the 
references in the identified studies for additional potential 
papers. Additional literature will be identified by contacting 
experts in the field and through searching of registers of 
ongoing studies. The review will include cost-effectiveness 
and economic modelling/evaluation studies and analytical 
observational epidemiology studies that have investigated 
the healthcare costs of asthma comorbidity. Two reviewers 
will independently screen studies and extract relevant 
data from included studies. Methodological quality of 
epidemiological studies will be assessed using the 
Effective Public Health Practice Project tool, while that of 
economic evaluation studies will be assessed using the 
Drummond checklist. This protocol has been published in 
International Prospective Register of Systematic Reviews 
(PROSPERO) database (No. CRD42016051005).
Ethics and dissemination As there are no primary data 
collected, formal NHS ethical review is not necessary. The 
findings of this systematic review will be disseminated 
in a peer-reviewed journal and presented at relevant 
conferences.
PROSPEROregistration number CRD42016051005.
IntroductIon
Asthma is a highly prevalent condition 
that is the reason behind many morbidity 
and mortality cases in the world.1 2 Asthma 
management and control can be influenced, 
among other things, by the presence of 
other comorbid conditions.3–7 Our recently 
completed scoping review investigating the 
prevalence of comorbidities among patients 
with asthma identified a number of conditions 
including, but not limited to depression, 
anxiety, rhinitis, gastro-oesophageal reflux 
disease (GORD) and obesity, may occur more 
frequently in people with asthma than in 
those without, leading to potential additional 
difficulties in asthma management.8–10 It has 
been shown that health-related quality of life 
and daily-life functionality are diminished, 
and the use of healthcare services is increased 
with the presence of comorbid condi-
tions.3 6 9–15 In addition, other studies showed 
that controlling these conditions at an early 
stage may improve asthma outcomes.6 12 14 15
These international studies focused on 
different study samples who had different 
comorbid conditions, explaining the 
discrepancies in their findings.16–18 While 
these have now assessed the healthcare and 
economic burden associated with asthma 
comorbidity,19–21 there has hitherto been 
no systematic attempt to synthesise and 
summarise the evidence that has emanated 
from existing studies.
This review builds on our earlier work,8 
which involved a scoping review of the recent 
landscape of asthma comorbidity; the purpose 
of the current work is to identify, appraise 
and synthesise the evidence on healthcare 
costs associated with asthma comorbidity.19–21
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Protocol
Strengths and limitations of this study
 ► This is the first systematic review to synthesise the 
evidence on the healthcare costs attributable to 
asthma comorbidity.
 ► A major limitation is that it may be difficult to employ 
meta-analysis as we anticipate studies with different 
study designs, definitions of costs and time periods.
 ► Based on previous work, we anticipate considerable 
difficulties in identifying information on the indirect 
costs associated with asthma comorbidities such as 
productivity loss and social and intangible costs. This 
review will therefore be focused on direct healthcare 
costs only, we recognise that it is a subset of overall 
costs.
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Methods
This protocol has been prepared following the Preferred 
Reporting Items for Systematic review and Meta-Analysis 
Protocols (PRISMA-P) approach.22 It has been published 
in International Prospective Register of Systematic 
Reviews database (no CRD42016051005).
types of studies
We will include economic modelling/evaluation and 
analytical epidemiological studies—that is, cohort, 
case-control and cross-sectional studies—that have inves-
tigated the healthcare costs of asthma comorbidity.
Editorials, animal studies, reviews, case studies,and 
case-series studies will be excluded.
Participants
We are interested in studies on participants with evidence 
of clinician-diagnosed asthma. There will be no restric-
tion concerning age or sex of participants.
comorbidities of interest
Comorbidity has been defined as ‘any distinct additional 
clinical entity that has existed or may occur during the 
clinical course of a patient who has the index disease 
under study’.23 We are interested in comorbidities that 
are not related to natural causes such as ageing, but rather 
those that are pathophysiologically related to asthma 
and have the potential to impact on asthma control, 
management and/or prognosis, regardless of whether 
they develop before or after asthma. These include, but 
are not limited to allergic diseases, chronic obstructive 
pulmonary disease, autoimmune disorders (eg, type 
1 diabetes), metabolic disorders (eg, type 2 diabetes, 
obesity), cardiovascular diseases, psychological dysfunc-
tion (anxiety, depression), hypertension and GORD. We 
grouped comorbidities according to the latest version of 
the International Classification of Diseases 10th Revision 
diagnosis codes.24
outcome
Healthcare costs of asthma comorbidities.
search methods
Databases
We will search for published studies, from 2007 to 2017, 
from the following databases: National Health Service 
Economic Evaluation Database, Google Scholar, Allied 
and Complementary Medicine Database, Global Health, 
Medline, Embase, Institute for Scientific Information 
(ISI) Web of Science, Cumulative Index to Nursing and 
Allied Health Literature and PsychINFO. Additional liter-
ature will be identified by searching the reference list of 
identified eligible studies and by searching the reposito-
ries of international conference proceedings, including 
ISI Conference Proceeding Citation Index and Zetoc 
(British Library). We will search the references in the 
identified studies for additional potential papers. Addi-
tional literature will be identified by contacting experts 
in the field and through searching of registers of ongoing 
studies.
Search strategy
We have developed a strategy in Medline (see 
online supplementary appendix) to retrieve relevant liter-
ature on the topic. This search strategy will be adapted 
in searching other databases. There will be no language 
restriction and, where possible, studies in languages other 
than English will be translated.
The databases will be searched for the period January 
2000 to January 2017. We have chosen 2000 as a start date 
while we are aware that there was limited work before 
the 2000s on the healthcare and economic burden of 
asthma,25 these studies focused exclusively on asthma 
without taking any comorbid conditions into consider-
ation.
Study selection
The articles retrieved from the database searches will 
be exported into EndNote reference management 
programme. Screening will be undertaken according to 
the inclusion and exclusion criteria. Two reviewers (KF 
and EV) will independently undertake the screening of 
the records (by title and/or abstract) for eligibility and a 
third reviewer (BN or AS or AP) will arbitrate in case of 
any disagreement to reach a consensus. Full text of eligible 
papers after the first screening will be reviewed again to 
confirm that the papers meet the inclusion and exclusion 
criteria. The screening process will be undertaken and 
reported according to the PRISMA recommendation.26
Data extraction
A customised data extraction form is being constructed 
to extract relevant data from all studies meeting our 
inclusion criteria. The form will first be piloted on few 
studies first. The data abstracted will include: author(s), 
publication year, geographical location of data collection, 
study design, aims and research questions, settings, popu-
lation/participants (n, mean age, gender), comorbidities 
studied, time period specific costs included, cost unit(s) 
and estimates of total costs, currency, price year, whether 
discounting was applied where relevant and key findings. 
Data extraction will be undertaken independently by two 
reviewers (KF and EV). Any differences will be resolved by 
discussion or if necessary arbitration by a third reviewer 
(BN or AS or AP).
data assessment and synthesis
Quality assessment
Two reviewers (KF and EV) will independently assess the 
quality of included studies and the potential for risk of 
bias will be evaluated. We will use the Drummond check-
list27 for assessing the methodological quality of economic 
evaluation and cost studies. Although there are many 
economic evaluation and reporting checklists, a lot of 
them have overlapping aspects. The Drummond check-
list focuses on the quality of the designs. Consensus will 
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be reached through discussion and arbitration by a third 
reviewer (BN or AS or AP) in event of any disagreement.
The quality of the broader study design will be evalu-
ated using the Effective Public Health Practice Project 
(EPHHP) tool.28 The EPHPP tool assesses different 
components of studies: design, biases and methods. The 
overall study rating will be judged as strong, moderate or 
weak based on the component ratings.
Data synthesis
We anticipate considerable methodological and statistical 
heterogeneity across studies, which will make it hard to 
conduct meta-analyses of the evidence base. A narrative 
synthesis will thus be employed as the primary approach 
to synthesise the data, but we will also consider the possi-
bility of meta-analysis using random-effects modelling if 
the data allow. If that is the case, then we will evaluate 
potential for publication bias using funnel plots and Begg 
and Egger tests.29 30
Subgroup analysis
Where possible, we will conduct subgroup analyses based 
on the categories of relevant sociodemographic charac-
teristics reported in the studies, particularly by age groups 
and gender.
 ► Age (will depend on how authors have reported it, 
but may include categorisation as follows):
 ► Children and young people <18 years
 ► Adults (≥18 years old)
 ► Gender
 ► Male
 ► Female
If the number of studies and data available show 
significant statistical heterogeneity, then we will conduct 
sensitivity analyses with regards to study quality by 
excluding studies at high risk of bias.
conclusIon
Asthma comorbidities have the potential to impact on 
asthma management, healthcare use and outcomes. We 
anticipate that this systematic review will build on our 
previous work on the epidemiology and outcomes of 
asthma8 31 32 and provide important insights into patterns 
of asthma comorbidity and the economic consequences 
to health systems of these comorbid disorders.
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